By admin 
The appointment of John Polson, Chairman and Managing Partner of the international law firm Fisher Phillips, to the Board of Directors at CureSearch for Children’s Cancer marks a significant expansion of the organization’s leadership during a period of record-breaking research efficiency. Polson, a seasoned legal professional with more than three decades of experience in high-level corporate governance and labor law, joins the board as CureSearch intensifies its efforts to bridge the funding gap between laboratory discovery and clinical application for pediatric oncology treatments.
This strategic addition to the CureSearch leadership team comes at a time when the organization is reporting unprecedented success in its "Catapult" funding model. While the national average for cancer research projects successfully transitioning from preclinical stages to clinical trials remains at a stagnant 8%, CureSearch-funded projects are currently achieving a 60% advancement rate. Polson’s background in managing large-scale operations across dozens of global offices is expected to provide the logistical and strategic oversight necessary to scale these high-impact initiatives.
A Career Defined by Leadership and Strategic Oversight
John Polson’s professional trajectory has been defined by his long-standing tenure at Fisher Phillips, one of the world’s leading firms specializing in labor and employment law. As Chairman and Managing Partner, Polson is responsible for the strategic direction, growth, and day-to-day operations of the firm’s 41 offices worldwide. His leadership has been instrumental in the firm’s inclusion in prestigious rankings such as The Best Lawyers in America and The Legal 500, accolades that reflect a commitment to excellence and high-stakes problem-solving.
In the context of a non-profit board, these skills are highly transferable. Managing a global legal enterprise requires a deep understanding of regulatory environments, risk management, and organizational scaling—elements that are critical for CureSearch as it navigates the complex landscape of federal drug approvals and international research collaborations. Polson’s appointment represents a trend in the non-profit sector where high-level corporate executives are recruited to bring private-sector efficiency to mission-driven organizations.
The Landscape of Pediatric Cancer Research
To understand the significance of Polson’s appointment, one must look at the current state of pediatric oncology. Despite cancer being the leading cause of death by disease for children in the United States, pediatric cancer research receives only a small fraction of the funding allocated to adult cancer research. This disparity often results in a "bottleneck" where promising therapies developed in academic labs fail to reach patients because they lack the financial backing required for expensive clinical trials.
CureSearch has positioned itself as a disruptor in this space. By focusing on translational research—the stage where a discovery is turned into a usable treatment—the organization aims to bypass traditional delays. The "60% success rate" cited by the organization is a metric that highlights their rigorous vetting process and their ability to identify projects with the highest potential for clinical success. Polson’s role on the board will involve overseeing the fiscal and operational frameworks that sustain this high-performance model.
A History of Philanthropic Synergy: Fisher Phillips and CureSearch
The relationship between John Polson and CureSearch is not a new development, but rather the culmination of years of collaborative effort. Under Polson’s guidance, Fisher Phillips has been a consistent advocate for childhood cancer awareness. The firm’s philanthropic arm, FP Cares, has served as a primary vehicle for this support.
One of the most notable collaborations was the "Notes of Hope" campaign. During this initiative, Fisher Phillips employees across its global network wrote thousands of handwritten letters to children undergoing cancer treatment. This campaign addressed the often-overlooked psychosocial aspect of the disease, providing emotional support to families during some of their most difficult moments. Beyond emotional support, the firm’s financial contributions have been substantial; FP Cares raised $200,000 to directly fund CureSearch’s research portfolio.
In recognition of these efforts, CureSearch previously honored Fisher Phillips with the "Champion for Cures" award. This history of engagement suggests that Polson’s transition to the Board of Directors is a natural progression of a long-standing commitment to the cause.
Official Responses and Strategic Vision
The announcement has been met with enthusiasm from both the legal and medical advocacy communities. John Polson expressed a personal connection to the mission, noting that the fight against childhood cancer is a cause close to his heart. He emphasized his desire to leverage his professional experience to provide hope to families and to drive the organization’s critical research work forward.
Kay Koehler, President and CEO of CureSearch, highlighted the specific value Polson brings to the table. "John’s proven leadership, deep commitment to social impact, and ability to build strong relationships will be invaluable," Koehler stated. She noted that his vision would help the organization "take our mission to the next level," particularly as CureSearch looks to expand its influence in the biotechnology and pharmaceutical sectors to encourage more investment in pediatric-specific drugs.
Chronology of the Partnership and Appointment
The timeline of Polson’s involvement with CureSearch illustrates a deepening commitment over several years:
- Early 2020s: Fisher Phillips establishes a formal philanthropic partnership with CureSearch through the FP Cares program.
- 2022-2023: The "Notes of Hope" campaign goes viral within the legal community, resulting in thousands of messages for pediatric patients.
- Late 2023: Fisher Phillips reaches a milestone of $200,000 in total funds raised for CureSearch, leading to the "Champion for Cures" recognition.
- Mid-2024: CureSearch reports that 60% of its preclinical projects are moving into clinical trials, creating a need for expanded board oversight to manage growth.
- Present: John Polson is officially appointed to the Board of Directors, joining a multidisciplinary team of oncologists, business executives, and patient advocates.
Broader Implications for Non-Profit Governance
Polson’s appointment reflects a broader shift in how modern non-profits operate. By integrating a legal heavyweight and a master of corporate operations into its board, CureSearch is adopting a "venture philanthropy" mindset. This approach treats charitable donations as investments in specific outcomes—in this case, the number of new drugs reaching the market.
For the legal industry, Polson’s move sets a precedent for how high-ranking partners can engage in corporate social responsibility (CSR) at a systemic level. It moves beyond mere checkbook philanthropy into active governance, where the strategic skills used to win cases and manage firms are used to solve public health crises.
Analyzing the Impact on Pediatric Treatment Pipelines
The 60% advancement rate for CureSearch-funded projects is the organization’s most compelling argument for its current strategy. In the pharmaceutical industry, the transition from preclinical "in-vitro" or "in-vivo" testing to Phase I human trials is often referred to as the "Valley of Death." Many promising compounds die here due to lack of funding, regulatory hurdles, or a lack of commercial incentive for pediatric-sized markets.
With Polson on the board, CureSearch is better equipped to navigate the "regulatory and contractual" side of this valley. His expertise in labor and employment law, while seemingly distant from oncology, involves the same core competencies required for large-scale project management: navigating federal compliance, managing diverse teams of experts, and ensuring that organizational resources are deployed with maximum efficiency.
Conclusion and Future Outlook
As John Polson begins his tenure on the CureSearch Board of Directors, the organization is poised for a period of significant growth. The goal remains clear: to ensure that every child diagnosed with cancer has access to treatments that are not only effective but also specifically designed for their developing bodies. Currently, many pediatric treatments are simply "scaled-down" versions of adult treatments, which can lead to lifelong side effects and secondary health issues.
By combining the medical expertise of its scientific advisory councils with the operational brilliance of leaders like Polson, CureSearch is building a robust framework to challenge the status quo of cancer research. The appointment serves as a signal to the medical community and donors alike that CureSearch is committed to a professional, high-output approach to ending childhood cancer. With Polson’s guidance, the organization aims to continue its trajectory of exceeding national averages and delivering tangible, life-saving results to the children and families who need them most.
